FINWIRES · TerminalLIVE
FINWIRES

Research Alert: CFRA Keeps Buy Rating On Shares Of Biomarin Pharmaceutical Inc.

By

-- CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:

We retain our target at $75, based on our NPV analysis. We lower our 2026 EPS estimate from $5.17 to $4.96. We raise our 2027 EPS view from $5.86 to $6.69. BMRN reported a solid Q1 2026, highlighted by the recent closing of the acquisition of Amicus Therapeutics, which is set to accelerate revenue growth to a forecasted 20% Y/Y for 2026. The deal adds two high potential commercial products, Galafold for Fabry disease and Pombiliti + Opfolda for Pompe disease, to BMRN's portfolio, supporting revenue diversification, in our view. BMRN's total revenues rose to $766M in Q1 (+3% Y/Y), slightly above expectations, supported by healthy patient demand for the enzyme therapies and Voxzogo. Yet, non-GAAP EPS of $0.76 missed expectations primarily due to increased operating expenses. Looking ahead, the integration of Amicus, advancing the pipeline with key data readouts expected in Q2, and driving continued commercial success of the portfolio will be key for BMRN.

Related Articles

Equities

Earnings Flash (SU) Suncor Energy Posts Q1 Adjusted Operating EPS C$1.93, vs. FactSet Est of C$1.74

$SU
Mining & Metals

Russel Metals Q1 Profit Jumps, Tops Estimates As Revenue Rises

Russel Metals (RUS.TO) after trade Tuesday reported a 67% jump in first-quarter earnings on record quarterly revenue, topping estimates.Russel posted a profit of C$72 million, or $1.30 per share, up from $43 million, or $0.75, a year earlier. In exceeded the consensus estimate of $0.76 compiled by FactSet analysts.Revenue rose 21% to to $1.41 billion, up from $1.17 billion, surpassing $1.38 billion.In the first quarter , the company also reported an EBITDA of $124 million, which was a 44% increase over the first quarter of 2025, and an 80% increase over the fourth quarter of 2025.The company's shares closed up $0.44 to $53.48 on the Toronto Stock Exchange.

$RUS.TO
Research

Research Alert: Celanese Misses Q1 Consensus Estimates, Provides Optimistic Q2 Guidance

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:CE reported Q1 2026 EPS of $0.85 vs. $0.54 in the prior year, missing consensus by $0.05, while revenue of $2.337B rose 6% sequentially but declined 2% Y/Y, missing estimates by $9M. Engineered Materials showed strong operational improvements with sales of $1.325B (+3% Y/Y) and operating margins expanding to 17% as operating profit surged to $221M from $94M, reflecting successful execution of product mix optimization and cost reduction initiatives. Management advanced structural actions including closure of the Singapore nylon facility and network enhancements across Asia and Europe. Management raised full-year FCF guidance to $700M-$800M and provided Q2 EPS guidance of $2.00-$2.40, with approximately $3.00 expected for the second half. The company targets net debt/operating EBITDA improvement to 4.8x through continued cash generation, though Q1 FCF of only $3M reflects seasonal working capital timing and highlights the importance of debt reduction given elevated leverage levels.

$CE